US Stock Market Move | BioNTech (BNTX.US) falls over 6% after terminating Phase 2 Cevumeran cancer immunotherapy trial.

On Friday, BioNTech (BNTX.US) opened lower, with an intraday decline of more than 9%. As of the time of this report, the decline narrowed to 6.79%, priced at $103.84. In terms of news, the company announced the termination of Phase 2 trials for the Cevumeran cancer immunotherapy. BioNTech SE stated that it has decided to terminate the Phase 2 clinical trial (BNT122-01; NCT04486378), a study evaluating the investigational personalized mRNA cancer immunotherapy autogene cevumeran (BNT122/RO7198457) as a monotherapy for patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II (high-risk) or Stage III colorectal cancer (CRC). Autogene cevumeran is co-developed by BioNTech and Genentech, a member of the Roche Group. The decision to terminate the clinical trial was made after discussions with Genentech.